Physician profile
Thomas Groner
NPI 1073510301
$193,294.43
in general payments reported to CMS, 2019-2025
22 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $970 · 2021: $31K · 2022: $36K · 2023: $31K · 2024: $29K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $15K · Consulting Fee: $11K · Food and Beverage: $4,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,365.00 |
| Travel and Lodging | $14,739.40 |
| Consulting Fee | $11,312.50 |
| Food and Beverage | $4,026.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $187,794.13 | 2019-2025 | Grafix, Stravix, Grafix Pl |
| Osiris Therapeutics INC. | $3,866.98 | 2019 | |
| Organogenesis INC. | $383.73 | 2019-2025 | Affinity, Puraply |
| Horizon Therapeutics Plc | $216.44 | 2019-2022 | |
| Misonix INC | $160.96 | 2019-2020 | |
| Convatec INC. | $94.08 | 2021-2025 | |
| Cashflow Solutions, LLC | $92.40 | 2023-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Pacira Pharmaceuticals Incorporated | $85.90 | 2019 | |
| Kerecis Limited | $85.32 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kci USA, INC. | $76.17 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $66.24 | 2021-2025 | Nuzyra |
| Integra Lifesciences Corporation | $65.12 | 2019-2021 | |
| Solventum Corporation | $59.16 | 2025 | Activ.A.C. |
| 3m Company | $55.25 | 2019 | |
| Medtronic, INC. | $40.89 | 2024 | Intellis Adaptivestim |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.07 | 2022-2023 | |
| Nevro Corp. | $36.77 | 2023 | Senza |
| B. Braun Medical INC. | $25.61 | 2019 | |
| Globus Medical, INC. | $16.71 | 2025 | Senza |
| Allergan, INC. | $13.27 | 2019 | |
| Merck Sharp & Dohme LLC | $11.17 | 2019 | |
| Reprise Biomedical, INC. | $11.06 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Groner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.